Welcome to our dedicated page for Mesa Laboratories news (Ticker: MLAB), a resource for investors and traders seeking the latest updates and insights on Mesa Laboratories stock.
Mesa Laboratories designs and manufactures life science tools and critical quality control solutions for regulated pharmaceutical, healthcare and medical device applications. The company reports through Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions and Clinical Genomics, covering indicators for sterilization and cleaning processes, protein analysis and peptide synthesis systems, calibration products and genetic analysis tools.
Recurring company news includes quarterly and fiscal-year results, segment performance commentary, regular cash dividend declarations, investor conference participation and governance updates such as leadership transitions. Updates often connect Mesa's product mix, end-market conditions, debt management and operating margins with demand from regulated life sciences customers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced a quarterly dividend of $0.16 per share, payable on June 15, 2023. Shareholders of record by the close of business on May 31, 2023 will receive this dividend. Mesa is recognized as a leading provider of life science tools and quality control solutions within the pharmaceutical and healthcare sectors, focusing on enhancing product integrity and safety. The company continues to navigate industry challenges, including potential risks related to competition and demand fluctuations. Further financial details can be found in its annual reports filed with the SEC.
Mesa Laboratories (NASDAQ:MLAB) has addressed the recent closure of Silicon Valley Bank, which has been placed under FDIC control. As of March 13, 2023, depositors can access their funds. Mesa reports that its cash and cash equivalents, totaling $26.1 million as of December 31, 2022, are securely held across multiple large financial institutions, mitigating risks associated with SVB. The company maintains that its cash flow and existing balance are adequate for ongoing working capital needs and contractual obligations. Mesa has minimal exposure with SVB, with deposits exceeding FDIC limits being under $500,000.
Mesa Laboratories, Inc. (NASDAQ:MLAB) plans to release its financial results for the fourth quarter and fiscal year ending March 31, 2023, on May 25, 2023, at 8:00 A.M. Eastern time. The company is recognized as a global leader in designing and manufacturing life science tools and critical quality control solutions, targeting regulated applications in sectors like pharmaceuticals, healthcare, and medical devices.
Mesa operates through four divisions: Sterilization and Disinfection Control, Biopharmaceutical Development, Clinical Genomics, and Calibration Solutions, focusing on product integrity and patient safety.
Mesa Laboratories, Inc. (NASDAQ: MLAB) has released its inaugural Environmental, Social, and Governance (ESG) Program Brochure on February 13, 2023. The brochure outlines Mesa's ongoing efforts in corporate responsibility and sustainability, emphasizing the company's mission of Protecting the Vulnerable®. Developed by Mesa's ESG Taskforce, the brochure reflects the company's commitment to improving patient care and fostering a sustainable environment for its employees and communities. CEO Gary Owens highlighted the importance of being a net positive contributor to society and the environment. For further details, the brochure can be accessed on the company's website.
Mesa Laboratories (NASDAQ:MLAB) reported its Q3 FY2023 results, revealing a 1% revenue decline to $54,287. Core organic revenue growth stood at 4.6%, despite external pressures such as currency shifts and COVID-related impacts. Operating income surged 235% to $3,402, while net income increased 122% to $451 or $0.08 per diluted share. The Clinical Genomics division was notably affected by the closure of Sema4's expanded carrier screening business, leading to a 10% organic revenue decline. Positive performance was noted in Sterilization & Disinfection Control, with an organic growth of 17.7% for the quarter. Management indicates ongoing cost reductions and a strategy focusing on long-term growth.